University of Mississippi Medical Center
umc.eduLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
126
Active
15
Phase 3
10
Total enrollment
13,109
Pipeline matrix
Showing 4 of 4 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Standardized Low-dose bolus IV Ketamine within 30 minutes of arrival and every 1 hour as needed for max of 3 doses. | — | — | — | — | — | 1 | |
| Empagliflozin 25 mg thrice-weekly post-hemodialysis dosing | — | — | — | — | — | 1 | |
| Empagliflozin 10 mg daily dosing | — | — | — | — | — | 1 | |
| 17 OHPC | — | — | — | — | — | 1 |
Next readouts
- 2026-05-04
- 2027-01-31
- 2029-08-31
Top conditions
- Hypertension8
- Obesity7
- Sickle Cell Disease4
- Asthma4
- Sedentary Behavior3
- Spinal Cord Injuries3
- Preeclampsia3
- Healthy2
Frequently asked questions about University of Mississippi Medical Center
- How many clinical trials does University of Mississippi Medical Center have on ClinicalTrials.gov?
- University of Mississippi Medical Center is listed as the lead sponsor on 126 clinical trials in ClinicalTrials.gov, 15 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Mississippi Medical Center's trials are in Phase 3?
- 10 of University of Mississippi Medical Center's trials are in Phase 3, spread across 4 active drug programs.
- What therapeutic areas does University of Mississippi Medical Center focus on?
- University of Mississippi Medical Center's most-studied conditions on ClinicalTrials.gov are Hypertension, Obesity, Sickle Cell Disease, Asthma, Sedentary Behavior.
- When are University of Mississippi Medical Center's next clinical trial readouts?
- University of Mississippi Medical Center has 3 upcoming primary-completion readouts tracked here; the soonest is “Empagliflozin in ESKD - A Feasibility Study”, expected around 2026-05-04.